Acute tumor lysis syndrome after thalidomide therapy in advanced hepatocellular carcinoma [2]

Oncologist

Volumn 11, Issue 1, 2006, Pages 87-88

  Lee, Chien Chang ^a   Wu, Yuan Huei ^a   Chung, Shen Hung ^a   Chen, Wen Jone ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Hepatocellular carcinoma; Thalidomide; Tumor lysis syndrome

Indexed keywords

ALLOPURINOL; ALPHA FETOPROTEIN; CREATININE; DIURETIC AGENT; GLUCOSE; INSULIN; LACTATE DEHYDROGENASE; THALIDOMIDE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; ALKALINIZATION; CANCER RECURRENCE; CANCER SIZE; CASE REPORT; CHEMOEMBOLIZATION; CREATININE BLOOD LEVEL; EMERGENCY WARD; FATALITY; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPERURICEMIA; JAUNDICE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LETTER; LIVER CELL CARCINOMA; LOW DRUG DOSE; MALE; METABOLIC ACIDOSIS; MONOTHERAPY; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME;

ANGIOGENESIS INHIBITORS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; THALIDOMIDE; TUMOR LYSIS SYNDROME;

EID: 31444455211     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.11-1-87     Document Type: Letter

References (6)

1. Zhu AX, Fuchs CS, Clark JW et al. A Phase II Study of Epirubicin and Thalidomide in Unresectable or Metastatic Hepatocellular Carcinoma. The Oncologist 2005;10:392-398.
2. Cany L, Fitoussi O, Boiron JM et al. Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma. J Clin Oncol 2002;20:2212.
3. Peuckmann V, Fisch M, Bruera E. Potential novel uses of thalidomide: focus on palliative care. Drugs 2000;60:273-292.
4. Harris E, Behrens J, Samson D et al. Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol 2003;122:160-161.
5. Spencer A, Robert A, Bailey M et al. No evidence for an adverse interaction between zoledronic acid and thalidomide: preliminary safety analysis from the Australasian Leukemia and Lymphoma Group MM6 Myeloma Trial. Blood 2003;102:383.
6. Hsu C, Chen CN, Chen LT et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 2003;65:242-249.